Dernières nouvelles pour Cigna (NYSE:CI) Stock

Cigna

Cigna Group

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 18 million US medical members covered as of December 2023.

The Cigna Group

AMUNDI INDIA B ETF

Citizens, Inc. Class A Common Stock ($1.00 Par)

Citizens Inc

CHINA MENGNIU DAIRY CO by China Mengniu Dairy Co., Ltd.

China Mengniu Dairy Co Ltd

CHINA MENGNIU DARY UN/ADR by China Mengniu Dairy Co., Ltd.

CHAMPION IRON LTD by Champion Iron Limited

Champion Iron Ltd

China Score Inc

BanColombia SA

COMML INTL BK S/ADR by Commercial International Bank Ltd.

Commercial International Bank - Egypt CIB

CIB MARINE BANCSHARES by CIB Marine Bancshares, Inc.

CIB Marine Bancshares Inc

COMMUTY INV BANCORP INC by Community Investors Bancorp, Inc.

Community Investors Bancorp Inc

First Trust NASDAQ Cybersecurity ETF

CIBL Inc

Capitol Investment Corp. VII

CHINA CONSTR BANK H by China Construction Bank Corp.

China Construction Bank Corp

CHINA CONSTR BK UNSP/ADR by China Construction Bank Corp.

SMS ALTERNATIVES INC by SMS Alternatives Inc.

SMS Alternatives Inc

COSCO SHIPPING HLDGS CO by COSCO SHIPPING Holdings Co Ltd.

COSCO SHIPPING Holdings Co Ltd

COSCO SHP HLDG UNSP/ADR by COSCO SHIPPING Holdings Co Ltd.

Capitol Investment Corp. VI

VictoryShares International High Div Volatility Wtd ETF

CLAL INSURANCE ENTERPRISE by CLAL INSURANCE ENTERPRISES HOLDINGS LTD.

CI EMERGING MARKET ALPHA USD UNT ETF

Ciena Corp

CIENA ORD

CHieru Co Ltd

CORPORACION INTERAMER B by Corporacion Intramericano Entretenimiento S.A.

Corporacion Interamericana de Entretenimiento SAB de CV

MFS Intermediate High Income Fund Common Stock

Mfs Intermediate High Income Fund

Cipher Mining Inc

Comp En De Mn Cemig ADS American Depositary Shares

Cia Energetica DE Minas Gerais - Cemig

Comp En De Mn Cemig ADS American Depositary Receipts

Colliers International Group Inc. - Subordinate Voting Shares

Colliers International Group Inc

Concorde International Group Ltd

CI GAMES SA by CI GAMES SA

COMPANHIA ENERG ADR REPG ONE PRF

CHINA MERCHANTS BK CO H by China Merchants Bank Co., Ltd.

China Merchants Bank Co Ltd

CHINA MRCHNTS BK UNSP/ADR by China Merchants Bank Co., Ltd.

CB INDUS PRODUCT HLDG BHD by CB Industrial Product Holding BHD

CB Industrial Product Holding Bhd

Blackrock Enhanced Cap&Inc Fund, Inc

CITIC SECURITIES CO LTD H by Citic Securities Co., Ltd.

CITIC Securities Co Ltd

CITIC SECURITIES UNSP/ADR by Citic Securities Co., Ltd.

TIANCI INTERNATIONAL INC by Tianci International Inc.

Tianci International Inc

Credit Suisse Asset Management Income Fund, Inc. Common Stock

Credit Suisse Asset Mgmt Income Fund Inc

VictoryShares International Volatility Wtd ETF

CHINA LIFE INS CO H SHS by China Life Insurance Company Limited

China Life Insurance Co Ltd

CAROLINA MILLS INC by Carolina Mills, Inc.

Chimera Investment Corporation Common Stock

Chimera Investment Corp

CIMB GROUP HLDGS BHD ORD by CIMB Group Holdings BHD

CIMB Group Holdings Bhd

CIMC ENRIC HLDGS LTD ORD by CIMC Enric Holdings Ltd.

CIMC Enric Holdings Ltd

Chimera Investment Corporation 9.000% Senior Notes due 2029

Chimera Investment Corporation 9.250% Senior Notes due 2029

Pideka Group Inc

CIMAREX ENERGY 8 1/8 PFD by Cimarex Energy Co.

Chimera Investment Corporation 8.00% Series A Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 8.00% Series B Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 7.75% Series C Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 8.00% Series D Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

CHINA INDUSTRIAL GRP INC by China Industrial Group, Inc.

China Industrial Group

ISHRS DOW JONES IND AVRG USD ETF

ISHR DJ IND AVG ETF

Cincinnati Financial Corporation - Common Stock

Cincinnati Financial Corp

Cingulate Inc

COINSILIUM GROUP LTD ORD by Coinsilium Group Ltd.

Coinsilium Group Ltd

CHINA TAIPING INS HLD ORD by China Taiping Insurance Holdings Co Ltd.

China Taiping Insurance Holdings Co Ltd

CI&T Inc

CRUCIAL INNOVATIONS CORP by CRUCIAL INNOVATIONS CORP.

CI GLOBAL ALPHA INNOVATION USD ETF

For dividend-paying companies, maintaining dividend growth is an essential way to demonstrate to investors that a firm is stable and enjoys long-term profitability. Dividend growth is also attractive to investors because it means an increasing passive income stream through stock ownership. Some investors also subscribe to the belief that dividend growth is an important factor in determining a company&#39;s stock price, as in the case of the dividend discount model.
Investors seeking to capitalize on dividend growth might seek out a targeted ETF like the ProShares S&amp;P 500 Dividend Aristocrats ETF (BATS: <a class="ticker" href="https://www.benzinga.com/stock/nobl#BATS">NOBL</a>), which tracks S&amp;P constituents that have steadily increased dividend payouts for at least 25 years.
<h2>CI: Significant Dividend Growth and Signs of Being Undervalued</h2>
The Cigna Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ci#NYSE">CI</a>) is a health services and insurance business that currently has an annualized dividend payout of $5.60. Though its dividend yield is just 1.65%, considered below ideal by many dividend investors, its dividend growth rate is sky-high. The company enjoys an annualized 3-year dividend growth rate of nearly 400%.
Beyond this significant dividend growth, CI presents a sustainable dividend payout ratio of just under 46%, meaning that its earnings comfortably cover its dividend payouts.
Analysts widely see Cigna shares as undervalued, as the company&#39;s stock has upside potential of almost 16% based on consensus price estimates. Cigna also offers stability found only among blue-chip stocks, as it has its origins in insurance companies dating back 200 hundred years.
<h2>CDW: Solid Dividend Gains Alongside Earnings History</h2>
CDW Corp.&nbsp;is an IT services company that most recently paid a quarterly dividend of 62 cents in August, about double the payout from the same time five years ago and 10 times the payout from a decade ago.
The firm has a strong history of dividend increases and an attractive dividend payout ratio of 30.96%, which should reassure investors that the company is managing its dividend payments effectively and sustainably.
Supporting the growth of CDW&#39;s dividend payments is its strong earnings history, and analysts expect that to continue based on a projected earnings growth rate of 9.0%. The company did recently report a decline in revenues amid a challenging period for the IT industry more broadly, but at the same time it has improved its gross margin to maximize its revenue potential as the industry-wide headwinds ease.
<h2>CTRA: Dividend Performance and Aggressive Buyback</h2>
Coterra Energy Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ctra#NYSE">CTRA</a>) has grown its dividend by about 26% per year for the last three years and now offers an annualized dividend of $0.84 and a fairly competitive dividend yield of 3.39%. Across the energy industry, dividend yields have tended to be strong as share prices have struggled relative to the broader market. Indeed, Coterra shares are down about 6% in the last year.
Like other energy firms, Coterra has been subjected to declining oil prices, leaving its production levels and profit margin to fluctuate. Still, Coterra has outperformed analyst expectations in operational metrics such as cash flow per share and Wall Street sees strong earnings growth of nearly 38% to come.
What helps Coterra stand out to dividend investors is its aggressive share buyback program to return capital to investors. The company completed buybacks totaling well over 100% of free cash flow in the second quarter. While this pace may not be sustainable over the long term, it nonetheless supports the view that Coterra shares are undervalued. Analysts have set an average price target of $32.24, more than 30% above current price levels.
<h2>Looking Beyond Dividend Growth</h2>
Dividend growth is just one important factor to consider when looking at dividend stocks. Investors should also watch for a company&#39;s dividend yield, a measure of how much a firm pays out in dividends relative to its stock price&mdash;a higher dividend yield may mean that the company provides a more enticing prospect for investors looking to maximize their dividend payout compared to how much they spend on a stock, but it can also mean that a company is not reinvesting its profits into its business to fuel expansion. Payout ratio&mdash;a measurement of a company&#39;s dividend relative to its income&mdash;is also revealing. Companies may pay significant dividends but have a negative payout ratio, potentially indicating losses in the latest period, which is typically unsustainable.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/3-dividend-growth-stocks-set-to-supercharge-your-portfolio/">3 Dividend Growth Stocks Set to Supercharge Your Portfolio</a>&quot; first appeared on MarketBeat.

Earnings

Large Cap

News

Sector ETFs

Dividends

Price Target

Buybacks

Markets

Analyst Ratings

Tech

Trading Ideas

Insurance

ETFs

CTRA

NOBL

3 Dividend Growth Stocks Set to Supercharge Your Portfolio

Texas Attorney General Ken Paxton has filed a lawsuit against several major insulin manufacturers and pharmacy benefit managers (PBMs), alleging a conspiracy to <a target="_blank" href="https://www.benzinga.com/markets/equities/24/08/40560002/governments-suing-pharmacy-benefit-managers-over-insulin-prices-have-long-benefited-from-their-r" rel="noreferrer noopener">inflate insulin prices</a>.
The <a target="_blank" href="https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-sues-big-pharma-drug-manufacturers-and-pharmacy-benefit-managers" rel="noreferrer noopener">lawsuit</a> targets pharmaceutical companies such as Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and PBMs, including Cigna Corp's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) Express Scripts and CVS Health Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) CVS Pharmacy, accusing them of engaging in an unlawful scheme to raise insulin prices.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices</a>.
According to the lawsuit, insulin manufacturers artificially raised the prices of their drugs while paying PBMs a significant, undisclosed portion in return for preferred placement in PBM offerings.
The PBMs allegedly rewarded the manufacturers with the highest list prices by giving their products preferred status while excluding more affordable alternatives.
These insulin drugs, which cost manufacturers less than $2 to produce, were introduced in the late 1990s at $20 per vial. However, prices have now soared to between $300 and $700 per vial.
Over the past decade, some manufacturers have raised insulin prices by as much as 1,000%.
Paxton expressed outrage over the alleged scheme, stating, "This is a disturbing conspiracy by which pharmaceutical companies were intentionally and artificially inflating the price of insulin. Big Pharma insulin manufacturers and PBMs worked together to take advantage of diabetes patients and drive prices as high as they could." He vowed to hold these companies accountable for their actions.
The complaint further claims that while PBMs have publicly positioned themselves as entities working to reduce drug prices and improve treatment access, their actions tell a different story.
The lawsuit argues that the PBMs have colluded with insulin manufacturers to manipulate the market for their financial gain, all at the expense of Texas diabetics and healthcare payors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41171469/uber-avride-join-forces-for-autonomous-delivery-partners-with-enso-for-low-emission-ev-tires" target="_blank" rel="noreferrer noopener">Uber &amp; Avride Join Forces for Autonomous Delivery; Partners With ENSO For Low-Emission EV Tires</a></li>
</ul>
Photo by towfiqu barbhuiya via unsplash

Government

Health Care

Legal

General

Texas Attorney General Sues Insulin Manufacturers and Pharmacy Benefit Managers Over Price-Fixing Conspiracy That Increased Prices by 1,000%

<a href="https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-sues-big-pharma-drug-manufacturers-and-pharmacy-benefit-managers">https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-sues-big-pharma-drug-manufacturers-and-pharmacy-benefit-managers</a>
Texas Attorney General Ken Paxton sued major insulin manufacturers and pharmacy benefit managers (&quot;PBMs&quot;)&mdash;including Eli Lilly, Express Scripts, CVS Pharmacy, and others&mdash;over a conspiracy to increase prices of insulin.&nbsp;
Through this conspiracy, the manufacturers artificially and willingly raised the prices of insulin then paid a significant, undisclosed portion back to the PBMs as a quid pro quo for inclusion in the PBMs&#39; standard offerings. The PBMs then granted preferred status to the manufacturer whose drug has the highest list price while excluding lower priced drugs. These synthetic insulin drugs, which today cost the manufacturers less than $2 to produce and were originally priced at $20 when released in the late 1990s, now range between $300 and $700. In the last decade alone, the manufacturers who are defendants in the lawsuit have increased the prices of their insulins up to 1,000%. Attorney General Paxton is suing because the insulin pricing scheme violates the Texas Deceptive Trade Practices Act, constitutes unjust enrichment, and represents an unlawful civil conspiracy.
&quot;This is a disturbing conspiracy by which pharmaceutical companies were intentionally and artificially inflating the price of insulin. Big Pharma insulin manufacturers and PBMs worked together to take advantage of diabetes patients and drive prices as high as they could,&quot; said Attorney General Paxton. &quot;These companies acted illegally and unethically to enrich themselves, and we will hold them accountable.&quot;
According to the complaint, &quot;While the PBM Defendants represent that they perform their services on behalf of their clients (including Texas payors) and diabetics to lower drug prices, increase access to affordable drugs, and promote diabetic health, these representations are false. Rather, the PBM Defendants have worked in coordination with the Manufacturer Defendants to distort the market for diabetic treatments to their benefit at the expense of Texas diabetics and payors.&quot;
Liston &amp; Deas, David Nutt &amp; Associates, the Cicala Law Firm, and Foreman Watkins Krutz are serving as outside counsel.

Texas Attor­ney Gen­er­al Ken Pax­ton Sues Big Phar­ma Drug Man­u­fac­tur­ers And Phar­ma­cy Ben­e­fit Man­agers For Con­spir­a­cy

Across the recent three months, 11 analysts have shared their insights on Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $405.36, a high estimate of $438.00, and a low estimate of $384.00. Marking an increase of 0.79%, the current average surpasses the previous average price target of $402.18. 
<img src="https://www.benzinga.com/files/images/story/2024/1727794839_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Cigna by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$422.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$384.00</td>
<td>$384.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$438.00</td>
<td>$435.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$410.00</td>
<td>$410.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$393.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cigna. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Cigna compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Cigna's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Cigna's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cigna analyst ratings.</a>
<h2>Discovering Cigna: A Closer Look</h2>
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 18 million US medical members covered as of December 2023.
<h3>Breaking Down Cigna's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3 months period, Cigna showcased positive performance, achieving a revenue growth rate of 24.4% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Cigna's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.56%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Cigna's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.75% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Cigna's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.0% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Cigna's debt-to-equity ratio is below the industry average. With a ratio of 0.77, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Cigna Through 11 Analysts

Cantor Fitzgerald analyst Sarah James reiterates Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and maintains $400 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Cigna, Maintains $400 Price Target

CVS Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) is reportedly considering a major restructuring that could involve separating its <a target="_blank" href="https://www.benzinga.com/quote/CVS" rel="noreferrer noopener">retail and insurance businesses</a>.
The move comes as the healthcare services company faces investor pressure and seeks to recover from a challenging financial period.
CVS Health is trading at an EBITDA multiple of 7x, which is significantly lower than key competitors like UnitedHealth Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) and Cigna Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), which trade at multiples of 14x and 9x, respectively.
This valuation gap underscores CVS's pressure to find a viable path forward amid growing competition and investor concerns.
These talks with financial advisers explore how a potential breakup would work, although no final decisions have been made yet.
Reuters report says the discussions, which remain confidential, include the possibility of unwinding CVS Health's $70 billion acquisition of Aetna in 2017, a deal that significantly expanded the company's insurance capabilities.
Now facing mounting difficulties in its retail and insurance sectors, CVS Health is assessing various strategies, including the potential split of its business units.
If the separation occurs, CVS Health could create two publicly traded companies, but the decision is pending approval from its board of directors.
Another point of debate is whether CVS Health's pharmacy benefits manager (PBM) should remain part of the retail division or be integrated into the insurance segment.
The final structure of any split will depend on internal deliberations, Although the Reuters report adds that CVS Health could still pursue a different approach.
As per a recent WSJ report, CVS Health is set to face renewed pressure as hedge fund&nbsp;Glenview Capital Management, led by founder&nbsp;Larry Robbins, plans to meet top executives, including CEO&nbsp;Karen Lynch, to <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/41091446/cvs-health-in-focus-as-activist-investor-prepares-for-high-level-talks" rel="noreferrer noopener">discuss operational improvements</a>.
The meeting with Glenview comes as part of Robbins' broader strategy to push for change.
In the second quarter, the pharmacy chain reported adjusted EPS of&nbsp;$1.83&nbsp;decreased from&nbsp;$2.21&nbsp;in the prior year, beating the consensus of $1.73.
The fall is primarily due to a decline in the Health Care Benefits segment's operating results, which reflect continued utilization pressure and the unfavorable impact of the company's Medicare Advantage star ratings for the 2024 payment year within&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40220306/cvs-health-reports-mixed-q2-earnings-lowers-2024-outlook-reshuffles-segment-management" rel="noreferrer noopener">the Medicare product line</a>.
CVS Health revised its adjusted EPS guidance to $6.40-$6.65&nbsp;from at least&nbsp;$7.00 versus the consensus of $6.98, reflecting continued pressure in the Health Care Benefits segment.
CVS Health decided to make leadership changes based on the current performance and outlook for the Health Care Benefits segment.&nbsp;
Brian Kane&nbsp;quit, and Karen Lynch,&nbsp;the CEO, assumed direct leadership of the Health Care Benefits segment.
Karen and Tom Cowhey, CVS Health's CFO, oversee the business's day-to-day management.
Price Action: At last check Tuesday, CVS stock was up 2.21% at $64.27 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41111918/slb-adnoc-drilling-patterson-uti-join-forces-to-accelerate-uaes-unconventional-oil-program" target="_blank" rel="noreferrer noopener">SLB, ADNOC Drilling, Patterson-UTI Join Forces To Accelerate UAE's Unconventional Oil Program</a>.</li>
</ul>
Image via Shutterstock

Rumors

Media

CVS Health Mulls Split Of Retail And Insurance Divisions To Address Financial Challenges: Report

Cigna Says Medicare Annual Enrollment Period Begins Oct. 15 And Continues Through Dec. 7

CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) is set to face renewed pressure as hedge fund Glenview Capital Management, led by founder Larry Robbins, plans to meet top executives, including CEO Karen Lynch, to discuss operational improvements.
The meeting with Glenview comes as part of Robbins&#8217; broader strategy to push for change, the Wall Street Journal reports.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/08/40437498/pharmacy-chains-like-cvs-health-walgreens-boots-alliance-confront-shifting-consumer-habits-and-pro" rel="noreferrer noopener">Pharmacy Chains Like CVS Health, Walgreens Boots Alliance Confront Shifting Consumer Habits And Profit Pressures</a>.
Robbins, who has built a substantial $700 million position in CVS, sees potential for the company to revitalize its struggling business without resorting to a breakup.
Robbins is expected to propose cost-cutting and restructuring strategies but will not push for a breakup of CVS. Another hedge fund has also built a notable position in the company, hinting at further pressure from investors.
CVS, one of the largest healthcare companies in the U.S., has seen its stock tumble 24% year-to-date amid multiple earnings downgrades.
In the second quarter, the pharmacy chain reported adjusted EPS of&nbsp;$1.83&nbsp;decreased from&nbsp;$2.21&nbsp;in the prior year, beating the consensus of $1.73. The fall is primarily due to a decline in the Health Care Benefits segment&#8217;s operating results, which reflect continued utilization pressure and the unfavorable impact of the company&#8217;s Medicare Advantage star ratings for the 2024 payment year within <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40220306/cvs-health-reports-mixed-q2-earnings-lowers-2024-outlook-reshuffles-segment-management" rel="noreferrer noopener">the Medicare product line</a>.
CVS Health revised its adjusted EPS guidance to $6.40-$6.65&nbsp;from at least&nbsp;$7.00 versus the consensus of $6.98, reflecting continued pressure in the Health Care Benefits segment.
The Wall Street report <a target="_blank" href="https://www.wsj.com/health/healthcare/glenview-capital-plans-push-for-changes-at-cvs-5df8aa8a?mod=latest_headlines" rel="noreferrer noopener">adds</a> that CVS had heavily invested in attracting seniors to its Aetna Medicare plans, but the move backfired, squeezing margins. The company is now revising its Medicare approach for 2025 to address these issues.
CVS Health decided to make leadership changes based on the current performance and outlook for the Health Care Benefits segment.&nbsp;
Brian Kane&nbsp;quit, and Karen Lynch,&nbsp;the CEO, assumed direct leadership of the Health Care Benefits segment.
Karen and Tom Cowhey, CVS Health&#8217;s CFO, oversee the business&#8217;s day-to-day management.
Recently, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health&#8217;s Caremark,&nbsp;Cigna Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) Express Scripts, and&nbsp;UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Optum—for allegedly engaging in unfair and anti-competitive practices that have inflated the list&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">price of insulin medications</a>.
The FTC has also highlighted significant concerns regarding consolidating pharmacies and health insurance companies, focusing on the influence of a few dominant PBMs <a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">on prescription drug prices</a>.
Price Action: CVS stock is up 3.27% at $63.39 during the premarket session at last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41075259/udemy-downgrade-analyst-warns-of-negative-riskreward-profile-while-demand-is-weak" target="_blank" rel="noreferrer noopener">Udemy Downgrade: Analyst Warns Of Negative Risk/Reward Profile While Demand Is Weak</a>.</li>
</ul>
Photo: Around the World Photos via Shutterstock

Movers

CVS Health in Focus as Activist Investor Prepares for High-Level Talks

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$32.50</td>
<td>$70.5K</td>
<td>38.1K</td>
<td>2.5K</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/04/24</td>
<td>$51.00</td>
<td>$32.5K</td>
<td>829</td>
<td>797</td>
</tr>
<tr>
<td>BNTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$120.00</td>
<td>$34.5K</td>
<td>1.3K</td>
<td>625</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$355.00</td>
<td>$71.7K</td>
<td>16</td>
<td>505</td>
</tr>
<tr>
<td>TGTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$40.00</td>
<td>$137.7K</td>
<td>2</td>
<td>383</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$175.00</td>
<td>$45.4K</td>
<td>513</td>
<td>382</td>
</tr>
<tr>
<td>BHVN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$45.00</td>
<td>$48.4K</td>
<td>74</td>
<td>365</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$60.00</td>
<td>$189.7K</td>
<td>4.5K</td>
<td>172</td>
</tr>
<tr>
<td>GMED</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$70.00</td>
<td>$31.6K</td>
<td>7</td>
<td>122</td>
</tr>
<tr>
<td>MNKD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$3.50</td>
<td>$30.0K</td>
<td>121</td>
<td>100</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option sweep that happens to be bullish, expiring in 116 day(s) on January 17, 2025. This event was a transfer of 1500 contract(s) at a $32.50 strike. This particular call needed to be split into 47 different trades to become filled. The total cost received by the writing party (or parties) was $70.5K, with a price of $47.0 per contract. There were 38163 open contracts at this strike prior to today, and today 2583 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option sweep with bearish sentiment. It expires in 11 day(s) on October 4, 2024. Parties traded 500 contract(s) at a $51.00 strike. This particular call needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $32.5K, with a price of $65.0 per contract. There were 829 open contracts at this strike prior to today, and today 797 contract(s) were bought and sold. 
• Regarding BNTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), we observe a call option sweep with bullish sentiment. It expires in 25 day(s) on October 18, 2024. Parties traded 150 contract(s) at a $120.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $34.5K, with a price of $230.0 per contract. There were 1345 open contracts at this strike prior to today, and today 625 contract(s) were bought and sold. 
• Regarding CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we observe a put option sweep with bullish sentiment. It expires in 4 day(s) on September 27, 2024. Parties traded 239 contract(s) at a $355.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $71.7K, with a price of $300.0 per contract. There were 16 open contracts at this strike prior to today, and today 505 contract(s) were bought and sold. 
• For TGTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), we notice a put option sweep that happens to be bearish, expiring in 116 day(s) on January 17, 2025. This event was a transfer of 82 contract(s) at a $40.00 strike. This particular put needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $137.7K, with a price of $1680.0 per contract. There were 2 open contracts at this strike prior to today, and today 383 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option sweep that happens to be bearish, expiring in 88 day(s) on December 20, 2024. This event was a transfer of 329 contract(s) at a $175.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $45.4K, with a price of $138.0 per contract. There were 513 open contracts at this strike prior to today, and today 382 contract(s) were bought and sold. 
• For BHVN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>), we notice a put option trade that happens to be bearish, expiring in 25 day(s) on October 18, 2024. This event was a transfer of 149 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $48.4K, with a price of $325.0 per contract. There were 74 open contracts at this strike prior to today, and today 365 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a call option trade with neutral sentiment. It expires in 53 day(s) on November 15, 2024. Parties traded 150 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $189.7K, with a price of $1265.0 per contract. There were 4588 open contracts at this strike prior to today, and today 172 contract(s) were bought and sold. 
• For GMED (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>), we notice a put option sweep that happens to be bearish, expiring in 88 day(s) on December 20, 2024. This event was a transfer of 102 contract(s) at a $70.00 strike. This particular put needed to be split into 31 different trades to become filled. The total cost received by the writing party (or parties) was $31.6K, with a price of $310.0 per contract. There were 7 open contracts at this strike prior to today, and today 122 contract(s) were bought and sold. 
• For MNKD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>), we notice a call option sweep that happens to be bullish, expiring in 53 day(s) on November 15, 2024. This event was a transfer of 100 contract(s) at a $3.50 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $300.0 per contract. There were 121 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

BHVN

BNTX

GMED

MNKD

TGTX

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 15 years by 6.46% on an annualized basis producing an average annual return of 18.32%. Currently, Cigna has a market capitalization of $99.13 billion. 
Buying $1000 In CI: If an investor had bought $1000 of CI stock 15 years ago, it would be worth $12,278.75 today based on a price of $354.59 for CI at the time of writing.
<h3>Cigna's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727105412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $12,000 Today

With the Federal Trade Commission (FTC) taking a scalpel to the pharmacy benefit managers (PBMs) of UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) and Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), investors are left wondering which health giant can best <a href="https://www.benzinga.com/general/health-care">weather the storm</a>.
The FTC's lawsuit, <a href="https://www.cnbc.com/2024/09/20/ftc-sues-drug-middlemen-for-allegedly-inflating-insulin-prices.html">targeting</a> these companies for allegedly inflating insulin prices, could have a major ripple effect across the healthcare industry—and that means stock volatility. 
So, which stock looks healthier?
<h1 class="wp-block-heading">UnitedHealth Group: Big &amp; Bold, But Under The Microscope</h1>
UnitedHealth Group&#8217;s OptumRx unit is at the heart of the FTC's lawsuit, and while UNH's sheer scale as a global leader in healthcare gives it plenty of muscle, it also makes it a big target. 
Analysts predict a modest <a href="https://www.benzinga.com/report/UNH">2.75% price movement</a> over the next 12 months, with a price target range of $591 to $680. UnitedHealth&#8217;s size could either serve as a shield or an anchor, depending on how the FTC&#8217;s hammer falls. 
For now, it's the heavyweight champ, but will its bulk keep it from dodging regulatory punches?
Read Also: <a href="https://www.benzinga.com/general/biotech/24/09/40820758/unitedhealth-follows-competitors-replaces-humira-with-lower-cost-biosimilars">UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars</a>
<h1 class="wp-block-heading">CVS Health: Retail Resilience Or Regulation Roadblock?</h1>
CVS Health, known for its 9,000-plus pharmacy locations and its PBM business Caremark, finds itself in the crosshairs, too.
Its integration with Aetna and recent Oak Street acquisition might help it spread risk, but the complexity of its operations also means more regulatory scrutiny. 
Analysts are predicting a price movement of around 6.36%, with a <a href="https://www.benzinga.com/report/CVS">12-month target of $63</a>. CVS is a diversified player, but being a jack-of-all-trades could make navigating the regulatory maze even trickier.
<h1 class="wp-block-heading">Cigna: Niche Focus, Bigger Moves?</h1>
Cigna, meanwhile, might just be the underdog to keep an eye on. Its PBM arm, Express Scripts, is a major player, but Cigna's more focused approach with self-funded plans and key government contracts could help it pivot more easily than its larger rivals. 
Analysts expect a more significant <a href="https://www.benzinga.com/report/CI">14.22% price movement</a> for Cigna, with a target range of $400 to $438. Cigna's smaller footprint in the broader health insurance landscape could allow it to sidestep the worst of the regulatory fallout and come out swinging.
<h1 class="wp-block-heading">Who's Got The Edge?</h1>
In this health stock showdown, the winner depends on how well these companies can adapt to the FTC's increasing scrutiny. 
UnitedHealth's size gives it strength but might make it a bigger target. CVS has a diversified portfolio but faces risks from its complexity. Cigna, while smaller, seems poised for the most price movement and could be the nimblest in dealing with the regulatory headwinds. 
Investors should keep a close eye on how this legal saga unfolds — there's more drama to come!
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40957261/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields</a></li>
</ul>
Photos: Shutterstock

Long Ideas

Regulations

UnitedHealth Vs. CVS Vs. Cigna: Which Health Stock Will Beat The FTC's Regulatory Heat?

On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark, Cigna Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) Express Scripts, and UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Optum—for allegedly engaging in unfair and anti-competitive practices that have inflated the list <a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">price of insulin medications</a>.
The <a target="_blank" href="https://www.ftc.gov/news-events/news/press-releases/2024/09/ftc-sues-prescription-drug-middlemen-artificially-inflating-insulin-drug-prices" rel="noreferrer noopener">complaint</a> accuses the PBMs of creating a system that benefits them financially by prioritizing drug rebates, forcing patients to pay higher costs for life-saving insulin. These PBMs, referred to as the Big Three, administer around 80% of prescriptions in the U.S.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38564498/federal-trade-commission-targets-junk-patent-listings-for-diabetes-weight-loss-asthma-drugs-from-" rel="noreferrer noopener">Federal Trade Commission Targets &#8216;Junk Patent Listings&#8217; For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca</a>.
The FTC claims that the PBMs abused their market power to inflate insulin prices by promoting a rebate system with drug manufacturers.
This system led to the exclusion of lower-priced insulin from formularies, further driving up the cost for vulnerable patients.
The result is higher out-of-pocket expenses for those needing essential diabetes medication.
For example, the list price of Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Humalog rose dramatically from $21 in 1999 to over $274 in 2017.
Despite the availability of lower-priced alternatives, PBMs favored higher-priced drugs due to the lucrative rebates they provided.
The FTC is also examining the role of drug manufacturers, including Eli Lilly, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), in driving up insulin prices, signaling potential further action against these companies.
The rebate-driven system excluded lower-priced insulins and allowed the Big Three PBMs to keep significant revenue in the form of rebates and fees, a strategy that hurt patients while benefiting the PBMs financially.
Vulnerable patients, such as those with high deductibles or coinsurance, bore the brunt of these inflated costs, paying more for their insulin than the overall net cost to insurers.
Price Action: At last check Friday, CVS stock was down 1.61% at $57.49, UNH stock was down 0.29% at $575.39, and CI stock was up 0.07% at $357.52.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40961594/mullen-automotive-gears-up-210m-ev-deal-in-dubai-delivers-first-units-to-volt-mobility" target="_blank" rel="noreferrer noopener">Mullen Automotive Gears Up $210M EV Deal In Dubai – Delivers First Units To Volt Mobility</a>.</li>
</ul>
Photo by towfiqu barbhuiya via unsplash

US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices

Jefferies analyst David Windley maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Buy and raises the price target from $402 to $422.

Jefferies Maintains Buy on Cigna, Raises Price Target to $422

Cigna Subsidiary Express Scripts Files Lawsuit Against FTC, Demands Withdrawal Of PBM Report

Cigna's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) short percent of float has fallen 3.23% since its last report. The company recently reported that it has 3.34 million shares sold short, which is 1.2% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cigna Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726166721_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cigna has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cigna's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cigna's peer group average for short interest as a percentage of float is 9.91%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(CI) - Analyzing Cigna's Short Interest

UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) reportedly announced on Tuesday that it will remove AbbVie Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) blockbuster drug Humira from some of its preferred reimbursement lists starting January 1, 2025. The company will recommend lower-cost biosimilar versions instead.
This move is part of a larger trend in the U.S. pharmaceutical market, as health plans seek to cut costs by promoting alternatives to high-priced drugs.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">FTC Investigation Uncovers Anti-Competitive Practices By Handful Of Pharmacy Benefit Managers, Including CVS Health, UnitedHealth</a>.
Reuters highlights that Amgen Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Amjevita, managed by its pharmacy benefits unit, Optum Rx, is among the biosimilars covered under UnitedHealth&#8217;s lists for commercial health plans.
With this decision, Optum becomes the last of the three largest U.S. pharmacy benefit managers (PBMs) to exclude Humira.
Cigna Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) announced last month that it would remove Humira from some of its lists in 2025, following a similar decision by CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark unit in April.
CVS&#8217;s action led to a swift shift, with more patients transitioning to Sandoz Group AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZNY#OTC">SDZNY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZXF#OTC">SDZXF</a>) biosimilar version of Humira in just three weeks than in the previous 15 months combined.
Cigna plans to cover biosimilars like Boehringer Ingelheim&#8217;s Cyltezo, Simlandi from Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), and Alvotech&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) products, including an unbranded version of Sandoz&#8217;s Hyrimoz, as replacements for Humira.
UnitedHealth noted that patients would still have access to Humira until the FDA designates the preferred biosimilars as interchangeable with the original drug, per the report. The FDA is expected to make this designation in 2025.
Despite the growing competition, AbbVie has managed to retain a dominant share of the U.S. Humira market throughout 2023. This has been achieved through favorable negotiations with PBMs, even as biosimilar alternatives from companies like Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) entered the market.
As per a Reuters report, Humira has still managed to retain over 80% of its patients even after facing lower-priced rivals in the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/04/38468317/arthritis-patients-cignas-evernorth-to-offer-humira-biosimilar-at-no-out-of-pocket-cost" rel="noreferrer noopener">U.S. over the past year</a>.
Following their launch last year, pharmacy benefit managers largely influenced patient access, with minimal incentive for doctors to switch to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39228916/abbvies-arthritis-drug-humira-retains-market-dominance-despite-biosimilar-competition-challenges-" rel="noreferrer noopener">these alternatives</a>.
In May, Cantor Fitzgerald said AbbVie had positioned itself to absorb Humira biosimilar erosion and achieve modest <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38899905/abbvie-is-successfully-positioned-to-absorb-humira-biosimilar-erosion-analyst" rel="noreferrer noopener">operational revenue growth</a>.
Price Action: UNH stock is down 2% at $587.07 at last check Wednesday.
Photo via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40817991/gsk-halts-herpes-simplex-virus-vaccine-development-clears-path-for-other-contenders-like-moderna-" target="_blank" rel="noreferrer noopener">GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech</a>.</li>
</ul>

Biotech

Equities

ABBV

ALVO

AMGN

SDZNY

SDZXF

TEVA

UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars

Shares of The Cigna Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ci#NYSE">CI</a>) have gained 25.6% in the past year compared with the industry&#39;s 18.2% growth. The Medical sector and the S&amp;P 500 composite index have rallied 9.3% and 21.2%, respectively, in the same time frame. CI has been well-poised for growth on the back of a sound membership base, solid Evernorth unit, acquisitions and expanding cash reserves.&nbsp;
Currently priced at $357.40, the stock is just 3.6% below its 52-week high of $370.64. This proximity underscores investor confidence and market optimism about Cigna&#39;s prospects.&nbsp;
The health insurer, presently carrying a Zacks Rank #3 (Hold), has an impressive record of beating estimates in each of the trailing four quarters, the average surprise being 3.83%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/a8/77228.jpg?v=810613562" />
Image Source: Zacks Investment Research
<h2>Robust Growth Prospects of CI Stock</h2>
The Zacks Consensus Estimate for Cigna&#39;s 2024 earnings is pegged at $28.48 per share, which indicates a 13.5% increase from the 2023 figure. The consensus mark for revenues is $239.1 billion, which implies 22.4% growth from the year-ago figure.&nbsp;
The Zacks Consensus Estimate for 2025 earnings is pegged at $31.80 per share, which implies an 11.7% improvement from the 2024 estimate. The consensus mark for revenues is $246.5 billion, implying a 3.1% rise from the 2024 estimate.
<h2>Cigna&#39;s Business Tailwinds</h2>
Cigna&#39;s performance is underscored its strong growth platforms, Evernorth and Cigna Healthcare. Evernorth is propelled by a range of specialty pharmacy services, significantly enhancing pharmacy revenues for the parent company. Pharmacy revenues saw a 31.8% year-over-year increase in the first half of 2024.&nbsp;
Conversely, Cigna Healthcare is strengthened by its sound customer base across the U.S. Healthcare business. This segment anticipates long-term average annual adjusted earnings growth in the band of 7-10%.&nbsp;
An expanding customer base leads to higher premiums, a critical revenue source for health insurers. As of June 30, 2024, Cigna served 19 million medical customers. The aging U.S. population is likely to drive continuous demand for its Medicare plans in the days ahead. In addition to premium growth, Cigna Healthcare benefits from ongoing product enhancements and new or extended partnerships with prominent healthcare systems.
Cigna strategically acquires companies to bolster its solutions and capabilities, broaden its geographical reach and reinforce its market presence. In alignment with its focus on high-growth platforms, it has divested its non-core health units. A robust cash balance and sufficient cash generation abilities allow the company to invest in business expansion and strategically allocate capital for share buybacks and dividends. Over the next five years, management anticipates cash flows of approximately $60 billion.
<h2>Stocks to Consider</h2>
Some better-ranked stocks in the Medical space are Universal Health Services, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>), The Ensign Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ensg#NASDAQ">ENSG</a>) and HCA Healthcare, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hca#NYSE">HCA</a>). Universal Health currently sports a Zacks Rank #1 (Strong Buy), and Ensign Group and HCA Healthcare carry a Zacks Rank #2 (Buy).
Universal Health&#39;s earnings surpassed the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 14.58%. The consensus estimate for UHS&#39; 2024 earnings indicates a rise of 51% from the year-ago number. The consensus mark for revenues indicates growth of 9.8% from the year-ago figure.&nbsp;
The Zacks Consensus Estimate for UHS&#39; earnings has moved 15% north in the past 30 days. Shares of Universal Health have gained 73.7% in the past year.
Ensign Group&#39;s earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 1.40%. The consensus estimate for ENSG&#39;s 2024 earnings indicates a rise of 14.1% from the year-ago number. The consensus mark for revenues implies an improvement of 13.1% from the year-ago figure.&nbsp;
The Zacks Consensus Estimate for ENSG&#39;s earnings has moved 0.7% north in the past 60 days. Shares of Ensign Group have risen 59.9% in the past year. &nbsp;
HCA Healthcare&#39;s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed the mark once, the average surprise being 8.24%. The consensus estimate for HCA&#39;s 2024 earnings indicates an improvement of 18.2% from the year-ago figure. The consensus mark for revenues implies growth of 8.9% from the year-ago figure.&nbsp;
The Zacks Consensus Estimate for HCA&#39;s earnings has moved 1.2% north in the past seven days. Shares of HCA Healthcare have rallied 42% in the past year.
<a href="https://www.zacks.com/stock/news/2334211/cigna-stock-gains-26-in-a-year-what-lies-ahead-for-investors?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2334211">To read this article on Zacks.com click here.</a>

Earnings Beats

Mid Cap

Management

ENSG

Cigna Stock Gains 26% in a Year: What Lies Ahead for Investors?

Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 10 years by 3.83% on an annualized basis producing an average annual return of 14.39%. Currently, Cigna has a market capitalization of $99.95 billion. 
Buying $100 In CI: If an investor had bought $100 of CI stock 10 years ago, it would be worth $390.66 today based on a price of $357.53 for CI at the time of writing.
<h3>Cigna's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725982221_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Cigna Stock In The Last 10 Years

Cigna: This Dividend Grower Could Be Worth Buying Now

Investing in growth stocks is appealing due to attractive pricing, stable business activity, easing inflation, and the Fed's gradual rate cuts, all of which create a favorable environment for capital gains. With a positive global economic outlook, it could be wise to consider investing in stocks that Wall Street loves for 2024, such as RTX (RTX), Cigna (CI), and General Dynamics (GD). Read on… The recent pullback in the U.S. market presents an opportunity to acquire growth stocks at more attractive prices. Stable U.S. business activity signals strong growth and resilience, creating a favorable environment for high-growth investments. Additionally, positive sentiment in sectors like defense and healthcare may lead to promising future opportunities.
Therefore, it may be wise for investors to consider investing in strong stocks that Wall Street loves for 2024, such as RTX Corporation (<a href="https://stocknews.com/stock/RTX/">RTX</a>), The Cigna Group (<a href="https://stocknews.com/stock/CI/">CI</a>), and General Dynamics Corporation (<a href="https://stocknews.com/stock/GD/">GD</a>), all of which have strong growth potential.
Inflation has eased to <a href="https://www.cnbc.com/2024/09/13/fed-will-ease-slowly-as-there-is-still-work-to-do-on-inflation-fitch.html">2.5% year-over-year</a>, the lowest since February 2021. As it stabilizes, companies could see improved profitability, making certain stocks more appealing. Additionally, the Federal Reserve's gradual rate cuts over the next 25 months are expected to create a favorable environment for stock market growth by reducing borrowing costs and boosting corporate investment.
Historically, gradual <a href="https://www.reuters.com/markets/rates-bonds/with-feds-rate-cut-hand-debate-swirls-over-how-big-move-2024-09-18/">Fed rate cuts</a> have fueled stock market rallies, creating opportunities for capital gains as monetary policy eases and inflation stabilizes. Amid this, growth stocks stand out for their above-average revenue growth, with companies frequently reinvesting profits to drive future expansion, making them a compelling choice for long-term investors.
Considering these conducive trends, let's analyze the fundamentals of the three growth picks mentioned above.
RTX Corporation (<a href="https://stocknews.com/stock/RTX/">RTX</a>)
RTX is an aerospace and defense company that provides systems and services for commercial, military, and government customers internationally. It operates through three segments: Collins Aerospace, Pratt &amp; Whitney, and Raytheon.
RTX's levered FCF grew at a CAGR of 13.1% over the past three years. Also, its EBITDA grew at a CAGR of 3.6% over the past three years.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/l/levered-free-cash-flow.asp">levered FCF</a> margin, RTX's 12.99% is 101.7% higher than the 6.44% industry average. Likewise, its 3.28% trailing-12-month Capex / Sales is 12.4% higher than the 2.92% industry average.
RTX's sales for the second quarter ending June 30, 2024, increased 7.7% from the year to $19.72 billion. Its adjusted net income attributable to common shareholders remained flat year-over-year at $1.90 billion, while its EPS rose 9.3% year-over-year to $1.41. Additionally, the company's free cash flow increased significantly from the previous year to $2.20 billion.
Street expects RTX's EPS and revenue for the quarter ending September 30, 2024, to increase 7.3% and 47.3% year-over-year to $1.34 and $19.83 billion, respectively. It surpassed the Street EPS estimates in each of the trailing four quarters. The stock has gained 68.6% over the past year to close the last trading session at $121.47.
RTX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect strong prospects. It has an overall rating of B, translating to a Buy in our proprietary system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It is ranked #21 out of 71 stocks in the <a href="https://stocknews.com/category/air-defense/">Air/Defense Services</a> industry. It has a B grade for Growth, Momentum, and Sentiment. <a href="https://stocknews.com/stock/RTX/">Click here</a> to see RTX's ratings for Value, Stability, and Quality.
The Cigna Group (<a href="https://stocknews.com/stock/CI/">CI</a>)
CI provides insurance and related services. It operates through its Evernorth Health Services and Cigna Healthcare segments. The company also offers permanent insurance contracts for financing employer-paid benefits.
CI's revenue grew at a CAGR of 9% over the past five years. Also, its total assets grew at a CAGR of 0.3% over the past three years.
In terms of the trailing-12-month EBIT margin, CI's 3.51% is 22.5% higher than the 2.87% industry average. Similarly, its 1.41x asset turnover ratio is 243.1% higher than the 0.41x industry average.
During the second quarter ended June 30, 2024, CI's adjusted revenues increased 24.4% year-over-year to $60.47 billion. Its adjusted income from operations rose 4.9% and 9.6% year-over-year to $1.91 billion, or $6.72 per share. Moreover, the company's pharmacy revenues came in at $45.10 billion, up 32.8% over the prior-year quarter.
Analysts expect CI's revenue for the quarter ending September 30, 2024, to increase 21.5% year-over-year to $59.59 billion. Its EPS for the same quarter is expected to grow 8.1% year-over-year to $7.32. It surpassed the EPS estimates in each of the trailing four quarters. Over the past nine months, CI's stock has gained 15.9% to close the last trading session at $345.62.
It's no surprise that CI has an overall rating of A, which translates to a Strong Buy in our proprietary POWR Ratings system.
It has a B grade for Growth, Value, Stability, and Quality. It is ranked #2 out of 10 stocks in the A-rated <a href="https://stocknews.com/category/health-insurance/">Medical - Health Insurance</a> industry. Beyond what we stated above, we also have given CI grades for Momentum and Sentiment. Get all the CI's ratings <a href="https://stocknews.com/stock/CI/">here</a>.
General Dynamics Corporation (<a href="https://stocknews.com/stock/GD/">GD</a>)
GD operates as a global aerospace and defense company through four segments: Aerospace, Marine Systems, Combat Systems, and Technologies.
On September 19, 2024, GDIT announced a $299 million contract from the Defense Information Systems Agency (DISA) to support and enhance the Pentagon's network infrastructure. The contract includes a one-year base period with two six-month options.
On September 13, 2024, GD's NASSCO announced a contract to build up to eight additional John Lewis-class fleet replenishment oilers for the U.S. Navy, starting with a $780 million award for the tenth ship. If all eight ships are built, the contract's total value could exceed $6.70 billion.
GD's EPS grew at a CAGR of 3.7% over the past three years. Likewise, its net income grew at a CAGR of 2.6% during the same period.
In terms of the trailing-12-month net income margin, GD's 7.89% is 26.9% higher than the 6.22% industry average. Its 6.39% trailing-12-month Return on Total Assets is 29.5% higher than the 4.94% industry average. Likewise, its 0.83x trailing-12-month asset turnover ratio is 6.6% higher than the industry average of 0.78x.
GD's revenue for the second quarter which ended on June 30, 2024, increased 18% year-over-year to $11.98 billion. Its operating earnings rose 20.2% from the year-ago quarter to $1.16 billion. Moreover, the company's net earnings amounted to $905 million and $3.26 per share, up 21.6% and 20.7% over the previous year's quarter, respectively.
For the quarter ending September 30, 2024, GD's EPS and revenue are expected to increase by 22.6% and 15.1% year-over-year to $3.73 and $12.17 billion, respectively. It has surpassed the consensus EPS and revenue estimates in each of the trailing four quarters. Over the past year, the stock has gained 37.5% to close the last trading session at $301.56.
GD's POWR Ratings reflect a robust outlook. It has an overall rating of B, which translates to a Buy in our proprietary system.
It is ranked #5 in the Air/Defense Services industry. It has a B grade for Growth, Momentum, Stability, and Sentiment. <a href="https://stocknews.com/stock/GD/">Click here</a> to access additional grades of GD for Value and Quality.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
RTX shares were trading at $121.16 per share on Thursday afternoon, up $0.26 (+0.22%). Year-to-date, RTX has gained 46.60%, versus a 21.55% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/rtx-ci-gd-3-growth-stocks-wall-street-loves-for-2024/>3 Growth Stocks Wall Street Loves for 2024</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Growth Stocks Wall Street Loves for 2024

In a report released yesterday, Lance Wilkes from Bernstein maintained a Buy rating on Cigna (CI – Research Report), with a price target of $411.00...

Comments

Cigna

Actualités

Dernières nouvelles pour Cigna (NYSE:CI) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL